Clinical trial
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic…
NCT00026221 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00026221 |
|---|---|
| Title | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma |
| Official title | A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Skin Melanoma |
| Intervention type | Biological |
| Interventions | Recombinant Interferon Alfa, Bevacizumab |
| Enrollment | 57 |
| Start date | Nov 1, 2001 |
| Primary completion | Nov 1, 2013 |
| Completion | Nov 1, 2013 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: